Abliva AB (NEVPF)
0.01
0.00 (0.00%)
USD |
OTCM |
Nov 13, 16:00
Abliva Enterprise Value: 11.86M for Nov. 13, 2024
Enterprise Value Chart
Historical Enterprise Value Data
Date | Value |
---|---|
November 13, 2024 | 11.86M |
November 12, 2024 | 11.86M |
November 11, 2024 | 11.86M |
November 08, 2024 | 11.86M |
November 07, 2024 | 11.86M |
November 06, 2024 | 11.86M |
November 05, 2024 | 11.86M |
November 04, 2024 | 11.86M |
November 01, 2024 | 11.86M |
October 31, 2024 | 11.86M |
October 30, 2024 | 11.86M |
October 29, 2024 | 11.86M |
October 28, 2024 | 11.86M |
October 25, 2024 | 11.86M |
October 24, 2024 | 11.86M |
October 23, 2024 | 11.86M |
October 22, 2024 | 11.86M |
October 21, 2024 | 11.86M |
October 18, 2024 | 11.86M |
October 17, 2024 | 11.86M |
October 16, 2024 | 11.86M |
October 15, 2024 | 11.86M |
October 14, 2024 | 11.86M |
October 11, 2024 | 11.86M |
October 10, 2024 | 11.86M |
Date | Value |
---|---|
October 09, 2024 | 11.86M |
October 08, 2024 | 11.86M |
October 07, 2024 | 11.86M |
October 04, 2024 | 11.86M |
October 03, 2024 | 11.86M |
October 02, 2024 | 11.86M |
October 01, 2024 | 11.86M |
September 30, 2024 | 11.86M |
September 27, 2024 | 11.86M |
September 26, 2024 | 11.86M |
September 25, 2024 | 11.86M |
September 24, 2024 | 11.86M |
September 23, 2024 | 11.86M |
September 20, 2024 | 11.86M |
September 19, 2024 | 11.86M |
September 18, 2024 | 11.86M |
September 17, 2024 | 11.86M |
September 16, 2024 | 11.86M |
September 13, 2024 | 11.86M |
September 12, 2024 | 11.86M |
September 11, 2024 | 11.86M |
September 10, 2024 | 11.86M |
September 09, 2024 | 11.86M |
September 06, 2024 | 11.86M |
September 05, 2024 | 11.86M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-5.872M
Minimum
Jun 30 2023
54.76M
Maximum
Oct 15 2021
14.42M
Average
13.82M
Median
May 08 2020
Enterprise Value Benchmarks
Oncopeptides AB | -- |
BioInvent International AB | 215.05M |
Hansa Biopharma AB | 278.10M |
BioArctic AB | 1.160B |
Camurus AB | 3.067B |
Enterprise Value Related Metrics
Net Income (Quarterly) | -2.414M |
Total Expenses (Quarterly) | 2.413M |
EPS Diluted (Quarterly) | -0.0019 |
Earnings Yield | -84.68% |
Normalized Earnings Yield | -84.91 |